Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.
Experimental Dementia Research Unit, Department of Experimental Medical Science, BMC B11, Lund University, Lund, Sweden.
Aging Cell. 2021 Aug;20(8):e13433. doi: 10.1111/acel.13433. Epub 2021 Jul 14.
Recent studies indicate a crucial role for neuronal glycogen storage and degradation in memory formation. We have previously identified alpha-amylase (α-amylase), a glycogen degradation enzyme, located within synaptic-like structures in CA1 pyramidal neurons and shown that individuals with a high copy number variation of α-amylase perform better on the episodic memory test. We reported that neuronal α-amylase was absent in patients with Alzheimer's disease (AD) and that this loss corresponded to increased AD pathology. In the current study, we verified these findings in a larger patient cohort and determined a similar reduction in α-amylase immunoreactivity in the molecular layer of hippocampus in AD patients. Next, we demonstrated reduced α-amylase concentrations in oligomer amyloid beta 42 (Aβ ) stimulated SH-SY5Y cells and neurons derived from human-induced pluripotent stem cells (hiPSC) with PSEN1 mutation. Reduction of α-amylase production and activity, induced by siRNA and α-amylase inhibitor Tendamistat, respectively, was further shown to enhance glycogen load in SH-SY5Y cells. Both oligomer Aβ stimulated SH-SY5Y cells and hiPSC neurons with PSEN1 mutation showed, however, reduced load of glycogen. Finally, we demonstrate the presence of α-amylase within synapses of isolated primary neurons and show that inhibition of α-amylase activity with Tendamistat alters neuronal activity measured by calcium imaging. In view of these findings, we hypothesize that α-amylase has a glycogen degrading function within synapses, potentially important in memory formation. Hence, a loss of α-amylase, which can be induced by Aβ pathology, may in part underlie the disrupted memory formation seen in AD patients.
最近的研究表明,神经元糖原的储存和降解在记忆形成中起着关键作用。我们之前已经鉴定出一种位于 CA1 锥体神经元突触样结构内的糖原降解酶——α-淀粉酶(α-amylase),并表明具有高α-淀粉酶拷贝数变异的个体在情节记忆测试中表现更好。我们报告称,阿尔茨海默病(AD)患者的神经元α-淀粉酶缺失,并且这种缺失与 AD 病理学的增加相对应。在当前的研究中,我们在更大的患者队列中验证了这些发现,并确定 AD 患者海马分子层中的α-淀粉酶免疫反应性也有类似的降低。接下来,我们证明了在寡聚体淀粉样β 42(Aβ)刺激的 SH-SY5Y 细胞和来自具有 PSEN1 突变的人诱导多能干细胞(hiPSC)的神经元中,α-淀粉酶浓度降低。通过 siRNA 和 α-淀粉酶抑制剂 Tendamistat 分别降低α-淀粉酶的产生和活性,进一步表明可增强 SH-SY5Y 细胞中的糖原负荷。然而,寡聚体 Aβ刺激的 SH-SY5Y 细胞和具有 PSEN1 突变的 hiPSC 神经元的糖原负荷均降低。最后,我们证明了α-淀粉酶存在于分离的原代神经元的突触内,并表明使用 Tendamistat 抑制α-淀粉酶活性会改变通过钙成像测量的神经元活动。鉴于这些发现,我们假设α-淀粉酶在突触内具有糖原降解功能,这可能对记忆形成很重要。因此,由 Aβ病理学引起的α-淀粉酶丧失可能部分导致 AD 患者记忆形成受损。